I03-Macromolecular Crystallography
|
Aiste
Dijokaite-Guraliuc
,
Raksha
Das
,
Daming
Zhou
,
Helen M.
Ginn
,
Chang
Liu
,
Helen M. E.
Duyvesteyn
,
Jiandong
Huo
,
Rungtiwa
Nutalai
,
Piyada
Supasa
,
Muneeswaran
Selvaraj
,
Thushan I.
De Silva
,
Megan
Plowright
,
Thomas A. H.
Newman
,
Hailey
Hornsby
,
Alexander J.
Mentzer
,
Donal
Skelly
,
Thomas G.
Ritter
,
Nigel
Temperton
,
Paul
Klenerman
,
Eleanor
Barnes
,
Susanna J.
Dunachie
,
Cornelius
Roemer
,
Thomas P.
Peacock
,
Neil G.
Paterson
,
Mark A.
Williams
,
David R.
Hall
,
Elizabeth E.
Fry
,
Juthathip
Mongkolsapaya
,
Jingshan
Ren
,
David I.
Stuart
,
Gavin R.
Screaton
Diamond Proposal Number(s):
[27009]
Open Access
Abstract: In November 2021 Omicron BA.1, containing a raft of new spike mutations emerged and quickly spread globally. Intense selection pressure to escape the antibody response produced by vaccines or SARS-CoV-2 infection then led to a rapid succession of Omicron sub-lineages with waves of BA.2 then BA.4/5 infection. Recently, many variants have emerged such as BQ.1 and XBB, which carry up to 8 additional RBD amino-acid substitutions compared to BA.2. We describe a panel of 25 potent mAbs generated from vaccinees suffering BA.2 breakthrough infections. Epitope mapping shows potent mAb binding shifting to 3 clusters, 2 corresponding to early-pandemic binding hotspots. The RBD mutations in recent variants map close to these binding sites and knock out or severely knock down neutralization activity of all but 1 potent mAb. This recent mAb escape corresponds with large falls in neutralization titre of vaccine or BA.1, BA.2 or BA.4/5 immune serum.
|
Mar 2023
|
|
I03-Macromolecular Crystallography
|
Jiandong
Huo
,
Aiste
Dijokaite-Guraliuc
,
Chang
Liu
,
Raksha
Das
,
Piyada
Supasa
,
Muneeswaran
Selvaraj
,
Rungtiwa
Nutalai
,
Daming
Zhou
,
Alexander J.
Mentzer
,
Donal
Skelly
,
Thomas G.
Ritter
,
Ali
Amini
,
Sagida
Bibi
,
Sandra
Adele
,
Sile Ann
Johnson
,
Neil G.
Paterson
,
Mark A.
Williams
,
David R.
Hall
,
Megan
Plowright
,
Thomas A. H.
Newman
,
Hailey
Hornsby
,
Thushan I.
De Silva
,
Nigel
Temperton
,
Paul
Klenerman
,
Eleanor
Barnes
,
Susanna J.
Dunachie
,
Andrew J.
Pollard
,
Teresa
Lambe
,
Philip
Goulder
,
Elizabeth E.
Fry
,
Juthathip
Mongkolsapaya
,
Jingshan
Ren
,
David I.
Stuart
,
Gavin R.
Screaton
Diamond Proposal Number(s):
[27009]
Open Access
Abstract: Variants of SARS CoV-2 have caused successive global waves of infection. These variants, with multiple mutations in the spike protein are thought to facilitate escape from natural and vaccine-induced immunity and often increase in the affinity for ACE2. The latest variant to cause concern is BA.2.75, identified in India where it is now the dominant strain, with evidence of wider dissemination. BA.2.75 is derived from BA.2 and contains four additional mutations in the receptor binding domain (RBD). Here we perform an antigenic and biophysical characterization of BA.2.75, revealing an interesting balance between humoral evasion and ACE2 receptor affinity. ACE2 affinity for BA.2.75 is increased 9-fold compared to BA.2; there is also evidence of escape of BA.2.75 from immune serum, particularly that induced by Delta infection which may explain the rapid spread in India, where BA.2.75 is now the dominant variant. ACE2 affinity appears to be prioritised over greater escape.
|
Dec 2022
|
|
|
Open Access
Abstract: Echoviruses, for which there are currently no approved vaccines or drugs, are responsible for a range of human diseases, for example echovirus 11 (E11) is a major cause of serious neonatal morbidity and mortality. Decay-accelerating factor (DAF, also known as CD55) is an attachment receptor for E11. Here, we report the structure of the complex of E11 and the full-length ectodomain of DAF (short consensus repeats, SCRs, 1–4) at 3.1 Å determined by cryo-electron microscopy (cryo-EM). SCRs 3 and 4 of DAF interact with E11 at the southern rim of the canyon via the VP2 EF and VP3 BC loops. We also observe an unexpected interaction between the N-linked glycan (residue 95 of DAF) and the VP2 BC loop of E11. DAF is a receptor for at least 20 enteroviruses and we classify its binding patterns from reported DAF/virus complexes into two distinct positions and orientations, named as E6 and E11 poses. Whilst 60 DAF molecules can attach to the virion in the E6 pose, no more than 30 can attach to E11 due to steric restrictions. Analysis of the distinct modes of interaction and structure and sequence-based phylogenies suggests that the two modes evolved independently, with the E6 mode likely found earlier.
|
Nov 2022
|
|
I03-Macromolecular Crystallography
|
Jiandong
Huo
,
Aiste
Dijokaite-Guraliuc
,
Rungtiwa
Nutalai
,
Raksha
Das
,
Daming
Zhou
,
Alexander J.
Mentzer
,
Elizabeth E.
Fry
,
Juthathip
Mongkolsapaya
,
Jingshan
Ren
,
David I.
Stuart
,
Gavin R.
Screaton
Diamond Proposal Number(s):
[27009]
Open Access
|
Nov 2022
|
|
I03-Macromolecular Crystallography
|
Aiste
Dijokaite-Guraliuc
,
Raksha
Das
,
Rungtiwa
Nutalai
,
Daming
Zhou
,
Alexander J.
Mentzer
,
Chang
Liu
,
Piyada
Supasa
,
Susanna J.
Dunachie
,
Teresa
Lambe
,
Elizabeth E.
Fry
,
Juthathip
Mongkolsapaya
,
Jingshan
Ren
,
Jiandong
Huo
,
David I.
Stuart
,
Gavin R.
Screaton
Diamond Proposal Number(s):
[27009]
Open Access
|
Nov 2022
|
|
I03-Macromolecular Crystallography
|
Aekkachai
Tuekprakhon
,
Jiandong
Huo
,
Rungtiwa
Nutalai
,
Aiste
Dijokaite-Guraliuc
,
Daming
Zhou
,
Helen M.
Ginn
,
Muneeswaran
Selvaraj
,
Chang
Liu
,
Alexander J.
Mentzer
,
Piyada
Supasa
,
Helen M. E.
Duyvesteyn
,
Raksha
Das
,
Donal
Skelly
,
Thomas G.
Ritter
,
Ali
Amini
,
Sagida
Bibi
,
Sandra
Adele
,
Sile Ann
Johnson
,
Bede
Constantinides
,
Hermione
Webster
,
Nigel
Temperton
,
Paul
Klenerman
,
Eleanor
Barnes
,
Susanna J.
Dunachie
,
Derrick
Crook
,
Andrew J.
Pollard
,
Teresa
Lambe
,
Philip
Goulder
,
Neil G.
Paterson
,
Mark A.
Williams
,
David R.
Hall
,
Elizabeth E.
Fry
,
Juthathip
Mongkolsapaya
,
Jingshan
Ren
,
David I.
Stuart
,
Gavin R.
Screaton
,
Christopher
Conlon
,
Alexandra
Deeks
,
John
Frater
,
Lisa
Frending
,
Siobhan
Gardiner
,
Anni
Jämsén
,
Katie
Jeffery
,
Tom
Malone
,
Eloise
Phillips
,
Lucy
Rothwell
,
Lizzie
Stafford
Diamond Proposal Number(s):
[27009]
Open Access
Abstract: The Omicron lineage of SARS-CoV-2, first described in November 2021, spread rapidly to become globally dominant and has split into a number of sub-lineages. BA.1 dominated the initial wave but has been replaced by BA.2 in many countries. Recent sequencing from South Africa’s Gauteng region uncovered two new sub-lineages, BA.4 and BA.5 which are taking over locally, driving a new wave. BA.4 and BA.5 contain identical spike sequences and, although closely related to BA.2, contain further mutations in the receptor binding domain of spike. Here, we study the neutralization of BA.4/5 using a range of vaccine and naturally immune serum and panels of monoclonal antibodies. BA.4/5 shows reduced neutralization by serum from triple AstraZeneca or Pfizer vaccinated individuals compared to BA.1 and BA.2. Furthermore, using serum from BA.1 vaccine breakthrough infections there are likewise, significant reductions in the neutralization of BA.4/5, raising the possibility of repeat Omicron infections.
|
Jun 2022
|
|
I03-Macromolecular Crystallography
I04-Macromolecular Crystallography
Krios I-Titan Krios I at Diamond
|
Rungtiwa
Nutalai
,
Daming
Zhou
,
Aekkachai
Tuekprakhon
,
Helen M.
Ginn
,
Piyada
Supasa
,
Chang
Liu
,
Jiandong
Huo
,
Alexander J.
Mentzer
,
Helen M. E.
Duyvesteyn
,
Aiste
Dijokaite-Guraliuc
,
Donal
Skelly
,
Thomas G.
Ritter
,
Ali
Amini
,
Sagida
Bibi
,
Sandra
Adele
,
Sile Ann
Johnson
,
Bede
Constantinides
,
Hermione
Webster
,
Nigel
Temperton
,
Paul
Klenerman
,
Eleanor
Barnes
,
Susanna J.
Dunachie
,
Derrick
Crook
,
Andrew J.
Pollard
,
Teresa
Lambe
,
Philip
Goulder
,
Neil G.
Paterson
,
Mark A.
Williams
,
David R.
Hall
,
Juthathip
Mongkolsapaya
,
Elizabeth E.
Fry
,
Wanwisa
Dejnirattisai
,
Jingshan
Ren
,
David I.
Stuart
,
Gavin R.
Screaton
,
Christopher
Conlon
,
Alexandra
Deeks
,
John
Frater
,
Lisa
Frending
,
Siobhan
Gardiner
,
Anni
Jämsén
,
Katie
Jeffery
,
Tom
Malone
,
Eloise
Phillips
,
Lucy
Rothwell
,
Lizzie
Stafford
Diamond Proposal Number(s):
[27009, 26983]
Open Access
Abstract: Highly transmissible Omicron variants of SARS-CoV-2 currently dominate globally. Here, we compare neutralization of Omicron BA.1, BA.1.1 and BA.2. BA.2 RBD has slightly higher ACE2 affinity than BA.1 and slightly reduced neutralization by vaccine serum, possibly associated with its increased transmissibility. Neutralization differences between sub-lineages for mAbs (including therapeutics) mostly arise from variation in residues bordering the ACE2 binding site, however, more distant mutations S371F (BA.2) and R346K (BA.1.1) markedly reduce neutralization by therapeutic antibody Vir-S309. In-depth structure-and-function analyses of 27 potent RBD-binding mAbs isolated from vaccinated volunteers following breakthrough Omicron-BA.1 infection reveals that they are focussed in two main clusters within the RBD, with potent right-shoulder antibodies showing increased prevalence. Selection and somatic maturation have optimized antibody potency in less-mutated epitopes and recovered potency in highly mutated epitopes. All 27 mAbs potently neutralize early pandemic strains and many show broad reactivity with variants of concern.
|
May 2022
|
|
I03-Macromolecular Crystallography
|
Wanwisa
Dejnirattisai
,
Jiandong
Huo
,
Daming
Zhou
,
Jiří
Zahradník
,
Piyada
Supasa
,
Chang
Liu
,
Helen M. E.
Duyvesteyn
,
Helen M.
Ginn
,
Alexander J.
Mentzer
,
Aekkachai
Tuekprakhon
,
Rungtiwa
Nutalai
,
Beibei
Wang
,
Aiste
Dijokaite
,
Suman
Khan
,
Ori
Avinoam
,
Mohammad
Bahar
,
Donal
Skelly
,
Sandra
Adele
,
Sile Ann
Johnson
,
Ali
Amini
,
Thomas
Ritter
,
Chris
Mason
,
Christina
Dold
,
Daniel
Pan
,
Sara
Assadi
,
Adam
Bellass
,
Nikki
Omo-Dare
,
David
Koeckerling
,
Amy
Flaxman
,
Daniel
Jenkin
,
Parvinder K.
Aley
,
Merryn
Voysey
,
Sue Ann
Costa Clemens
,
Felipe Gomes
Naveca
,
Valdinete
Nascimento
,
Fernanda
Nascimento
,
Cristiano
Fernandes Da Costa
,
Paola Cristina
Resende
,
Alex
Pauvolid-Correa
,
Marilda M.
Siqueira
,
Vicky
Baillie
,
Natali
Serafin
,
Gaurav
Kwatra
,
Kelly
Da Silva
,
Shabir A.
Madhi
,
Marta C.
Nunes
,
Tariq
Malik
,
Peter J. M.
Openshaw
,
J. Kenneth
Baillie
,
Malcolm G.
Semple
,
Alain R.
Townsend
,
Kuan-Ying A.
Huang
,
Tiong Kit
Tan
,
Miles W.
Carroll
,
Paul
Klenerman
,
Eleanor
Barnes
,
Susanna J.
Dunachie
,
Bede
Constantinides
,
Hermione
Webster
,
Derrick
Crook
,
Andrew J.
Pollard
,
Teresa
Lambe
,
Neil G.
Paterson
,
Mark A.
Williams
,
David R.
Hall
,
Elizabeth E.
Fry
,
Juthathip
Mongkolsapaya
,
Jingshan
Ren
,
Gideon
Schreiber
,
David I.
Stuart
,
Gavin R.
Screaton
Diamond Proposal Number(s):
[27009]
Abstract: On the 24th November 2021 the sequence of a new SARS CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titres of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic as well as Alpha, Beta, Gamma, Delta are substantially reduced or fail to neutralize. Titres against Omicron are boosted by third vaccine doses and are high in cases both vaccinated and infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of a large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses, combining mutations conferring tight binding to ACE2 to unleash evolution driven by immune escape, leading to a large number of mutations in the ACE2 binding site which rebalance receptor affinity to that of early pandemic viruses.
|
Jan 2022
|
|
I03-Macromolecular Crystallography
|
Kuan-Ying A.
Huang
,
Daming
Zhou
,
Tiong Kit
Tan
,
Charles
Chen
,
Helen M. E.
Duyvesteyn
,
Yuguang
Zhao
,
Helen M.
Ginn
,
Ling
Qin
,
Pramila
Rijal
,
Lisa
Schimanski
,
Robert
Donat
,
Adam
Harding
,
Javier
Gilbert-Jaramillo
,
William
James
,
Julia A.
Tree
,
Karen
Buttigieg
,
Miles
Carroll
,
Sue
Charlton
,
Chia-En
Lien
,
Meei-Yun
Lin
,
Cheng-Pin
Chen
,
Shu-Hsing
Cheng
,
Xiaorui
Chen
,
Tzou-Yien
Lin
,
Elizabeth E.
Fry
,
Jingshan
Ren
,
Che
Ma
,
Alain R.
Townsend
,
David I.
Stuart
Diamond Proposal Number(s):
[27009]
Open Access
Abstract: Background: Administration of potent anti-receptor-binding domain (RBD) monoclonal antibodies has been shown to curtail viral shedding and reduce hospitalization in patients with SARS-CoV-2 infection. However, the structure-function analysis of potent human anti-RBD monoclonal antibodies and its links to the formulation of antibody cocktails remains largely elusive.
Methods: Previously, we isolated a panel of neutralizing anti-RBD monoclonal antibodies from convalescent patients and showed their neutralization efficacy in vitro. Here, we elucidate the mechanism of action of antibodies and dissect antibodies at the epitope level, which leads to a formation of a potent antibody cocktail.
Results: We found that representative antibodies which target non-overlapping epitopes are effective against wild type virus and recently emerging variants of concern, whilst being encoded by antibody genes with few somatic mutations. Neutralization is associated with the inhibition of binding of viral RBD to ACE2 and possibly of the subsequent fusion process. Structural analysis of representative antibodies, by cryo-electron microscopy and crystallography, reveals that they have some unique aspects that are of potential value while sharing some features in common with previously reported neutralizing monoclonal antibodies. For instance, one has a common VH 3-53 public variable region yet is unusually resilient to mutation at residue 501 of the RBD. We evaluate the in vivo efficacy of an antibody cocktail consisting of two potent non-competing anti-RBD antibodies in a Syrian hamster model. We demonstrate that the cocktail prevents weight loss, reduces lung viral load and attenuates pulmonary inflammation in hamsters in both prophylactic and therapeutic settings. Although neutralization of one of these antibodies is abrogated by the mutations of variant B.1.351, it is also possible to produce a bi-valent cocktail of antibodies both of which are resilient to variants B.1.1.7, B.1.351 and B.1.617.2.
Conclusions: These findings support the up-to-date and rational design of an anti-RBD antibody cocktail as a therapeutic candidate against COVID-19.
|
Nov 2021
|
|
I03-Macromolecular Crystallography
|
Chang
Liu
,
Daming
Zhou
,
Rungtiwa
Nutalai
,
Helen M. E.
Duyvesteyn
,
Aekkachai
Tuekprakhon
,
Helen M.
Ginn
,
Wanwisa
Dejnirattisai
,
Piyada
Supasa
,
Alexander J.
Mentzer
,
Beibei
Wang
,
James Brett
Case
,
Yuguang
Zhao
,
Donal T.
Skelly
,
Rita E.
Chen
,
Sile Ann
Johnson
,
Thomas G.
Ritter
,
Chris
Mason
,
Tariq
Malik
,
Nigel
Temperton
,
Neil G.
Paterson
,
Mark A.
Williams
,
David R.
Hall
,
Daniel K.
Clare
,
Andrew
Howe
,
Philip J. R.
Goulder
,
Elizabeth E.
Fry
,
Michael S.
Diamond
,
Juthathip
Mongkolsapaya
,
Jingshan
Ren
,
David I.
Stuart
,
Gavin R.
Screaton
Diamond Proposal Number(s):
[27009]
Open Access
Abstract: Alpha-B.1.1.7, Beta-B.1.351, Gamma-P.1 and Delta-B.1.617.2 variants of SARS-CoV-2 express multiple mutations in the spike protein (S). These may alter the antigenic structure of S, causing escape from natural or vaccine-induced immunity. Beta is particularly difficult to neutralize using serum induced by early pandemic SARS-CoV-2 strains and is most antigenically separated from Delta. To understand this, we generated 674 mAbs from Beta infected individuals and performed a detailed structure-function analysis of the 27 most potent mAbs: one binding the spike N-terminal domain (NTD), the rest the receptor binding domain (RBD). Two of these RBD-binding mAbs recognise a neutralizing epitope conserved between SARS-CoV-1 and -2, whilst 18 target mutated residues in Beta: K417N, E484K, and N501Y. There is a major response to N501Y including a public IgVH4-39 sequence, with E484K and K417N also targeted. Recognition of these key residues underscores why serum from Beta cases poorly neutralizes early pandemic and Delta viruses.
|
Nov 2021
|
|